Investigation on Safety, Tolerability, and Pharmacokinetics of Single Doses of NNC0113-0987 in Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 02 Mar 2017
Price : $35 *
At a glance
- Drugs NN 9926 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- 28 Feb 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 03 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 25 Sep 2012 New trial record